Reported about 7 hours ago
All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals, have agreed to participate in the second round of price talks established by the Inflation Reduction Act. Under the Biden administration, this initiative aims for greater transparency in Medicare drug price negotiations, with an initial offer for each drug slated for June 1, 2025. The negotiations target major medications, including diabetes treatment Ozempic and cancer drugs like Ibrance.
Source: YAHOO